3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Triple Negative Breast Neoplasms
2
Sarcoma
2
Recurrence
2
Neoplasms
2
Glioma
2
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
10
fludarabine
6
Doxorubicin
3
tazemetostat
2
sargramostim
2
pembrolizumab
2
fludarabine phosphate
2
Radiotherapy
2
Radiation
2
ribociclib
1
poly ICLC
1
peposertib
1
pegfilgrastim
1
liposomal doxorubicin
1
itacitinib
1
cixutumumab
1
baricitinib
1
aldesleukin
1
Specimen Handling
1
Rifampin
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Itraconazole
1
Immunotherapy, Adoptive
1
Immune Checkpoint Inhibitors
1
Ifosfamide
1
INCB039110
1
Filgrastim
1
Dehydroepiandrosterone
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Sarcoma, Synovial
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled